ATE126695T1 - Gehirnspezifische arzneimittelabgabe. - Google Patents

Gehirnspezifische arzneimittelabgabe.

Info

Publication number
ATE126695T1
ATE126695T1 AT83902034T AT83902034T ATE126695T1 AT E126695 T1 ATE126695 T1 AT E126695T1 AT 83902034 T AT83902034 T AT 83902034T AT 83902034 T AT83902034 T AT 83902034T AT E126695 T1 ATE126695 T1 AT E126695T1
Authority
AT
Austria
Prior art keywords
brain
dhc
blood
dihydropyridine
drug
Prior art date
Application number
AT83902034T
Other languages
English (en)
Inventor
Nicholas S Bodor
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/379,316 external-priority patent/US4479932A/en
Priority claimed from US06/475,493 external-priority patent/US4622218A/en
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of ATE126695T1 publication Critical patent/ATE126695T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AT83902034T 1982-05-18 1983-05-12 Gehirnspezifische arzneimittelabgabe. ATE126695T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/379,316 US4479932A (en) 1982-05-18 1982-05-18 Brain-specific drug delivery
US46154383A 1983-01-27 1983-01-27
US06/475,493 US4622218A (en) 1982-05-18 1983-03-15 Testicular-specific drug delivery

Publications (1)

Publication Number Publication Date
ATE126695T1 true ATE126695T1 (de) 1995-09-15

Family

ID=27409446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83902034T ATE126695T1 (de) 1982-05-18 1983-05-12 Gehirnspezifische arzneimittelabgabe.

Country Status (9)

Country Link
EP (6) EP0224283A3 (de)
AT (1) ATE126695T1 (de)
AU (1) AU567433B2 (de)
CA (2) CA1253856A (de)
DE (1) DE3382795T2 (de)
ES (1) ES8502087A1 (de)
IE (1) IE69557B1 (de)
IT (1) IT1171851B (de)
WO (1) WO1983003968A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082853A (en) * 1984-02-29 1992-01-21 Bodor Nicholas S Brain-specific analogues of centrally acting amines
US4933438A (en) * 1984-02-29 1990-06-12 University Of Florida Brain-specific analogues of centrally acting amines
US4771059A (en) * 1984-02-29 1988-09-13 University Of Florida Brain-specific analogues of centrally acting amines
JPS61501562A (ja) * 1984-02-29 1986-07-31 ユニバ−シティ・オブ　フロリダ 中枢作用アミン類の脳特異性類似化合物
WO1986000898A1 (en) * 1984-07-19 1986-02-13 University Of Florida Compounds for site-enhanced delivery of radionuclides and uses thereof
EP0191788A1 (de) * 1984-07-19 1986-08-27 University Of Florida Neue radiopharmazeutische verbindungen und chelatierungsmittel nützlich bei ihrer herstellung
US4963688A (en) * 1984-07-19 1990-10-16 University Of Florida Compounds for site-enhanced delivery of radionuclides and uses thereof
US4764598A (en) * 1985-08-22 1988-08-16 The United States Of America As Represented By The Department Of Energy Precursors to radiopharmaceutical agents for tissue imaging
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
US4888427A (en) * 1987-04-07 1989-12-19 University Of Florida Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
US5079366A (en) * 1987-04-07 1992-01-07 University Of Florida Quarternary pyridinium salts
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
EP0386644B1 (de) * 1989-03-10 1997-06-04 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Reagenzien zum Nachweis von Drogen
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
KR101301577B1 (ko) * 2010-08-20 2013-08-29 주식회사 바이오에프디엔씨 니코티노일 펩타이드 유도체 및 그를 포함하는 화장료 조성물
CN104136431B (zh) 2011-12-21 2017-03-15 小野药品工业株式会社 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物
JP2019508505A (ja) * 2016-03-14 2019-03-28 スフェラ ファーマ ピーブイティー リミテッドＳｐｈａｅｒａ Ｐｈａｒｍａ Ｐｖｔ． Ｌｔｄ． トリゴネリンベースの化合物
WO2018054723A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054721A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054711A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018065182A1 (en) 2016-10-04 2018-04-12 Basf Se Reduced quinoline compounds as antifuni agents
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides
WO2018134127A1 (en) 2017-01-23 2018-07-26 Basf Se Fungicidal pyridine compounds
WO2018184882A1 (en) 2017-04-06 2018-10-11 Basf Se Pyridine compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962447A (en) 1973-12-26 1976-06-08 Interx Research Corporation Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and method of using same
US3929813A (en) 1973-12-26 1975-12-30 Interx Research Corp Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and process for preparing same
US4069322A (en) * 1976-10-12 1978-01-17 Interx Research Corporation Pro-drugs for the improved delivery of certain selected anti-inflammatory steroids
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents

Also Published As

Publication number Publication date
WO1983003968A1 (en) 1983-11-24
EP0224283A3 (de) 1988-09-21
IE831149L (en) 1983-11-18
EP0224283A2 (de) 1987-06-03
EP0222425A3 (de) 1988-09-21
EP0256577A2 (de) 1988-02-24
EP0256577A3 (de) 1988-07-06
DE3382795T2 (de) 1996-02-15
EP0221588A2 (de) 1987-05-13
DE3382795D1 (de) 1995-09-28
EP0222425A2 (de) 1987-05-20
IT8348327A0 (it) 1983-05-18
CA1327566C (en) 1994-03-08
ES522489A0 (es) 1984-12-16
EP0110955A1 (de) 1984-06-20
ES8502087A1 (es) 1984-12-16
EP0262696A3 (de) 1988-07-20
AU567433B2 (en) 1987-11-19
CA1253856A (en) 1989-05-09
IE931149L (en) 1983-11-18
IT1171851B (it) 1987-06-10
EP0110955B1 (de) 1995-08-23
EP0221588A3 (de) 1988-09-21
IE69557B1 (en) 1996-10-02
EP0262696A2 (de) 1988-04-06
AU1703483A (en) 1983-12-02

Similar Documents

Publication Publication Date Title
DE3382795T2 (de) Gehirnspezifische arzneimittelabgabe.
SE8800731L (sv) Fenylkarbamat
DE69623608T2 (de) Zusammensetzung zur verbesserten elektroübertragunslieferung von wirkstoff
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
DE3682257D1 (de) Liposomzusammensetzung.
YU59704A (sh) Farmaceutske formulacije derivata platine
NO970507L (no) Blanding for frigjöring av medikamenter gjennom slimhinner
DE3779260D1 (de) Penetrationsverbesserer fuer die transdermale verabreichung von systemisch wirksamen arzneimitteln.
RU96119798A (ru) Трехъядерные катионные комплексы платины, обладающие противоопухолевой активностью, и фармацевтические композиции, содержащие эти комплексы
KR900014406A (ko) 세펨 화합물 및 이의 제조방법
FR2312243A1 (fr) Nouvelles propargyl-2-phenylamino-imidazolines-(2), leurs sels d'addition avec des acides, les medicaments les renfermant et procedes pour leur preparation
BE857778A (fr) Nouvelles 2-phenylamino-imidazolines-(2) substituees, leurs sels d'addition avec des acides, les medicaments les renfermant
KR880001596A (ko) 디하이드로피리딘 화합물-함유 뇌기능이상 치료제
Cavallito et al. Modification of rates of gastrointestinal absorption of drugs II. Quaternary ammonium salts
NZ331051A (en) Instant release forms of gelled active substances
KR850006429A (ko) 새로운 시아노이미다졸 누클레오시드 유도체 및 그 제조방법
FR2573308B1 (fr) Procede de solubilisation, au moment de l'emploi, d'un principe actif lipophile dans une solution aqueuse, en vue de son administration par voie intraveineuse
KR900701273A (ko) 진토성 에르골린 유도체
KR870001144A (ko) Nn-디메틸에틸옥사이드가 함유된 약제조성물 및 그의 생산방법
Kovacic et al. Anticancer quinones and quinolines: mode of action via electron transfer and oxidative stress
FR2395028A2 (fr) Derives pyridiniques, leur preparation et leurs application therapeutique
FR2510577B1 (fr) Composes organiques azotes extraits de plantes et leurs derives, leur preparation et leurs utilisations therapeutiques, notamment en tant qu'agents antineoplastiques
FR2220256A1 (en) 1,1'-Dialkyl-biguanide theophyllin-7-acetates - with hypocholesterolaemic and hypolipamic activity
KR870001153A (ko) 디페녹시에틸아민 유도체가 함유된 약제조성물 및 그의 생산방법
BE880648A (fr) Nouvelles formes galeniques d'administration de medicaments par voie orale, aliberation programmee et leurs procedes de preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time